{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T05:07:44Z","timestamp":1784524064143,"version":"3.55.0"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T00:00:00Z","timestamp":1757289600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>This study aimed to investigate serum neurofilament light chain (sNFL) levels in patients with myasthenia gravis (MG) and explore its potential as a biomarker for disease stratification. A total of 60 MG patients and 29 normal controls (NCs) were enrolled, with no significant differences in age or gender between the two groups. MG patients were stratified by MGFA classification, QMG scores, antibody status, phenotypic subtypes, onset age, and gender. Results showed that MG patients had significantly higher sNFL levels (median: 12.7\u202fpg.\/mL) compared to NCs (median: 9.1\u202fpg.\/mL; <jats:italic>p<\/jats:italic>\u202f=\u202f0.0176). Subgroup analyses revealed that sNFL levels in MGFA-II patients (median: 13.1\u202fpg.\/mL) were significantly elevated compared to NCs (<jats:italic>p<\/jats:italic>\u202f=\u202f0.0437), with no statistical difference in MGFA-I. Patients with QMG scores 7\u201315 (median: 13.4\u202fpg.\/mL) had higher sNFL levels than those with scores 0\u20136 (<jats:italic>p<\/jats:italic>\u202f=\u202f0.0207) and showed significant differences from NCs (<jats:italic>p<\/jats:italic>\u202f=\u202f0.0023). Late-onset MG (LOMG) patients (median: 13.4\u202fpg.\/mL) had higher sNFL levels than early-onset cases (<jats:italic>p<\/jats:italic>\u202f=\u202f0.0368), and age was mildly correlated with sNFL in MG (<jats:italic>p<\/jats:italic>\u202f=\u202f0.0477). ROC analysis showed moderate diagnostic performance of sNFL for distinguishing LOMG vs. NCs (&amp;gt;50\u202fyears) was 0.9464 (specificity 89.29%, sensitivity 90%), and for female MG vs. female NCs was 0.8091. In conclusion, sNFL levels are elevated in MG patients, particularly in severe and late-onset cases, suggesting its potential as a biomarker for disease stratification and severity assessment.<\/jats:p>","DOI":"10.3389\/fmed.2025.1652698","type":"journal-article","created":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T06:16:39Z","timestamp":1757312199000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Serum neurofilament light chain levels in myasthenia gravis patients with and without symptoms"],"prefix":"10.3389","volume":"12","author":[{"given":"Jie","family":"Lv","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruichen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingna","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyue","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengdi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,8]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1002\/mds.29027","article-title":"Neurofilament light protein as a potential blood biomarker for Huntington\u2019s disease in children","volume":"37","author":"Byrne","year":"2022","journal-title":"Mov Disord"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1089\/vim.2020.0126","article-title":"Detection of IgM and IgG antibodies to human parvovirus B19 in sera of patients with Thymoma-associated myasthenia gravis","volume":"34","author":"Jia","year":"2021","journal-title":"Viral Immunol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1212\/WNL.55.1.16","article-title":"Myasthenia gravis: recommendations for clinical research standards","volume":"55","author":"Jaretzki","year":"2000","journal-title":"Neurology"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"e066445","DOI":"10.1136\/bmjopen-2022-066445","article-title":"Patient-reported Burden of myasthenia gravis: baseline results of the international prospective, observational, longitudinal real-world digital study MyRealWorld-MG","volume":"13","author":"Dewilde","year":"2023","journal-title":"BMJ Open"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1111\/ene.13979","article-title":"Clinical analysis of Chinese anti-low-density-lipoprotein-receptor-associated protein 4 antibodies in patients with myasthenia gravis","volume":"26","author":"Li","year":"2019","journal-title":"Eur J Neurol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1007\/s00415-017-8514-z","article-title":"Screening for lipoprotein receptor-related protein 4-, Agrin-, and titin-antibodies and exploring the autoimmune Spectrum in myasthenia gravis","volume":"264","author":"Cordts","year":"2017","journal-title":"J Neurol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia gravis","volume":"5","author":"Gilhus","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.jcrc.2018.01.003","article-title":"Characteristics, incidence, and outcome of patients admitted to the intensive care unit with myasthenia gravis","volume":"45","author":"Al-Bassam","year":"2018","journal-title":"J Crit Care"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1038\/s41467-020-14612-6","article-title":"Serum Neurofilament light levels in Normal aging and their association with morphologic brain changes","volume":"11","author":"Khalil","year":"2020","journal-title":"Nat Commun"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"a018309","DOI":"10.1101\/cshperspect.a018309","article-title":"Neurofilaments and neurofilament proteins in health and disease","volume":"9","author":"Yuan","year":"2017","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1111\/jnc.14542","article-title":"A motor neuron strategy to save time and energy in neurodegeneration: adaptive protein stoichiometry","volume":"146","author":"Zucchi","year":"2018","journal-title":"J Neurochem"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1136\/jnnp-2021-327129","article-title":"Comparison of CSF and serum neurofilament light and heavy chain as differential diagnostic biomarkers for ALS","volume":"93","author":"Halbgebauer","year":"2022","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"938","DOI":"10.3389\/fnins.2021.689938","article-title":"Neurofilament proteins as biomarkers to monitor neurological diseases and the efficacy of therapies","volume":"15","author":"Yuan","year":"2021","journal-title":"Front Neurosci"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.celrep.2025.115382","article-title":"Secreted neurofilament light chain after neuronal damage induces myeloid cell activation and neuroinflammation","volume":"44","author":"Oi","year":"2025","journal-title":"Cell Rep"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"3077","DOI":"10.1161\/STROKEAHA.119.026410","article-title":"NfL (neurofilament light chain) levels as a predictive marker for long-term outcome after ischemic stroke","volume":"50","author":"Uphaus","year":"2019","journal-title":"Stroke"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1136\/jnnp.36.2.244","article-title":"Neurogenic muscle involvement in myasthenia gravis: a clinical and histopathological study","volume":"36","author":"Oosterhuis","year":"1973","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1097\/WCO.0b013e328364c079","article-title":"Myasthenia gravis and the neuromuscular junction","volume":"26","author":"Querol","year":"2013","journal-title":"Curr Opin Neurol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1097\/MCO.0000000000000267","article-title":"Neuromuscular junction degeneration in muscle wasting","volume":"19","author":"Rudolf","year":"2016","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"3485","DOI":"10.3390\/ijms23073485","article-title":"The role of CCL2\/CCR2 axis in cerebral ischemia-reperfusion injury and treatment: from animal experiments to clinical trials","volume":"23","author":"Geng","year":"2022","journal-title":"Int J Mol Sci"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1136\/jnnp-2018-320106","article-title":"Neurofilament light chain as a biomarker in neurological disorders","volume":"90","author":"Gaetani","year":"2019","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1212\/WNL.0000000000003107","article-title":"CSF Neurofilament light: a universal risk biomarker in multiple sclerosis?","volume":"87","author":"Khalil","year":"2016","journal-title":"Neurology"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S1043-0679(99)70018-3","article-title":"Myasthenia gravis: clinical features, pathogenesis, evaluation, and medical management","volume":"11","author":"Heitmiller","year":"1999","journal-title":"Semin Thorac Cardiovasc Surg"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1093\/brain\/awac328","article-title":"The multifaceted role of Neurofilament light chain protein in non-primary neurological diseases","volume":"146","author":"Abu-Rumeileh","year":"2023","journal-title":"Brain"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/S1474-4422(16)00070-3","article-title":"CSF and blood biomarkers for the diagnosis of Alzheimer\u2019s disease: a systematic review and Meta-analysis","volume":"15","author":"Olsson","year":"2016","journal-title":"Lancet Neurol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"2945","DOI":"10.1002\/mds.28779","article-title":"Neurofilament light chain as a biomarker for cognitive decline in Parkinson disease","volume":"36","author":"Aamodt","year":"2021","journal-title":"Mov Disord"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"104970","DOI":"10.1016\/j.ebiom.2024.104970","article-title":"Guidance for use of neurofilament light chain as a cerebrospinal fluid and blood biomarker in multiple sclerosis management","volume":"101","author":"Freedman","year":"2024","journal-title":"EBioMedicine"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"8487","DOI":"10.1038\/s41467-023-42320-4","article-title":"Para-infectious brain injury in COVID-19 persists at follow-up despite attenuated cytokine and autoantibody responses","volume":"14","author":"Michael","year":"2023","journal-title":"Nat Commun"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1007\/s13365-020-00889-2","article-title":"Serum and cerebrospinal fluid Neurofilament light chain in patients with central nervous system infections caused by varicella-zoster virus","volume":"26","author":"Tyrberg","year":"2020","journal-title":"J Neurovirol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1080\/00365513.2020.1730434","article-title":"Reference interval and preanalytical properties of serum neurofilament light chain in Scandinavian adults","volume":"80","author":"Hviid","year":"2020","journal-title":"Scand J Clin Lab Invest"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"fcac174","DOI":"10.1093\/braincomms\/fcac174","article-title":"Establishment of reference values for plasma neurofilament light based on healthy individuals aged 5-90 years","volume":"4","author":"Simr\u00e9n","year":"2022","journal-title":"Brain Commun"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/s41392-024-01823-2","article-title":"Tumor biomarkers for diagnosis, prognosis and targeted therapy","volume":"9","author":"Zhou","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1007\/s00415-016-8045-z","article-title":"Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the guidelines of the German neurological society","volume":"263","author":"Melzer","year":"2016","journal-title":"J Neurol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"120380","DOI":"10.1016\/j.jns.2022.120380","article-title":"Neurofilaments in neurologic disorders and beyond","volume":"441","author":"Mak","year":"2022","journal-title":"J Neurol Sci"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1111\/ene.15565","article-title":"Role of autoantibody levels as biomarkers in the Management of Patients with myasthenia gravis: a systematic review and expert appraisal","volume":"30","author":"Meisel","year":"2023","journal-title":"Eur J Neurol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1056322","DOI":"10.3389\/fneur.2022.1056322","article-title":"Serum neurofilament light chain in myasthenia gravis subgroups: an exploratory cohort and case\u2013control study","volume":"13","author":"Stascheit","year":"2023","journal-title":"Front Neurol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1186\/s12967-024-05767-7","article-title":"CSF and blood levels of Neurofilaments, T-tau, P-tau, and Abeta-42 in amyotrophic lateral sclerosis: a systematic review and Meta-analysis","volume":"22","author":"Agah","year":"2024","journal-title":"J Transl Med"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1652698\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T06:16:40Z","timestamp":1757312200000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1652698\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,8]]},"references-count":36,"alternative-id":["10.3389\/fmed.2025.1652698"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1652698","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,8]]},"article-number":"1652698"}}